| scholarly article | Q13442814 |
| P2093 | author name string | G C Prendergast | |
| W Du | |||
| P F Lebowitz | |||
| P2860 | cites work | Post-translational modifications of p21rho proteins | Q24293581 |
| PRK1 is targeted to endosomes by the small GTPase, RhoB | Q24312153 | ||
| Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton | Q41462575 | ||
| Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells | Q41546925 | ||
| Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor | Q41546932 | ||
| Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. | Q41563742 | ||
| Ras farnesyltransferase: a new therapeutic target | Q41596375 | ||
| Inhibition of Ras prenylation: a novel approach to cancer chemotherapy | Q41615096 | ||
| Cyclin dependent kinase inhibitors | Q41617198 | ||
| The assembly of integrin adhesion complexes requires both extracellular matrix and intracellular rho/rac GTPases | Q41984711 | ||
| Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription | Q42799520 | ||
| Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo | Q42800460 | ||
| The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments | Q42823387 | ||
| Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. | Q42823924 | ||
| Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. | Q42827718 | ||
| Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. | Q42827736 | ||
| Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts | Q42831499 | ||
| The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation | Q42835291 | ||
| A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells | Q47761479 | ||
| Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. | Q50904345 | ||
| Characterization of the phosphorylation sites and the surrounding amino acid sequences of the p21 transforming proteins coded for by the Harvey and Kirsten strains of murine sarcoma viruses. | Q53563970 | ||
| Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. | Q54177555 | ||
| Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice | Q71803596 | ||
| A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines | Q71805034 | ||
| Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956 | Q71805041 | ||
| Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB | Q73427445 | ||
| Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice | Q74356083 | ||
| Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a | Q24324559 | ||
| Intracellular localization of the P21rho proteins | Q24642838 | ||
| The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors | Q27860467 | ||
| High-efficiency transformation of mammalian cells by plasmid DNA | Q27860469 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| Protein prenyltransferases | Q28277579 | ||
| RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG | Q28298035 | ||
| Focal adhesions, contractility, and signaling | Q28299775 | ||
| Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice | Q28369454 | ||
| The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts | Q28571019 | ||
| Rho GTPases and signaling networks | Q28646215 | ||
| Protein prenylation: molecular mechanisms and functional consequences | Q29618038 | ||
| A role for Rho in Ras transformation | Q33723020 | ||
| A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis | Q33995709 | ||
| Xenopus oocyte germinal-vesicle breakdown induced by [Val12]Ras is inhibited by a cytosol-localized Ras mutant | Q34300969 | ||
| K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors | Q34427029 | ||
| Identification of Ras farnesyltransferase inhibitors by microbial screening | Q36165226 | ||
| Involvement of the GTP binding protein Rho in constitutive endocytosis in Xenopus laevis oocytes | Q36236019 | ||
| Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation | Q36556010 | ||
| Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. | Q36572588 | ||
| Posttranscriptional regulation of cellular gene expression by the c-myc oncogene | Q36753045 | ||
| Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein | Q36816986 | ||
| rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase | Q36894019 | ||
| Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity | Q37108753 | ||
| Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity | Q38288609 | ||
| Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest | Q40016944 | ||
| Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic | Q40745426 | ||
| Functional interaction between RhoB and the transcription factor DB1. | Q40985886 | ||
| Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. | Q41001860 | ||
| RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation | Q41041302 | ||
| Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines | Q41088805 | ||
| The polyproline region of p53 is required to activate apoptosis but not growth arrest. | Q41093439 | ||
| Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? | Q41094489 | ||
| Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. | Q41127508 | ||
| Rho family GTPases: the cytoskeleton and beyond | Q41166791 | ||
| Regulation of receptor-mediated endocytosis by Rho and Rac. | Q41185352 | ||
| ADP-ribosylation of the G protein Rho inhibits integrin regulation of tumor cell growth | Q41197828 | ||
| Regulation of the actin cytoskeleton, integrins and cell growth by the Rho family of small GTPases | Q41203870 | ||
| Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor | Q41234843 | ||
| Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton | Q41334369 | ||
| Critical role of Rho in cell transformation by oncogenic Ras. | Q41335003 | ||
| Regulation of Ras-related RhoB protein expression during the cell cycle. | Q41344933 | ||
| ADP-ribosylation of Rho enhances adhesion of U937 cells to fibronectin via the alpha 5 beta 1 integrin receptor | Q41349879 | ||
| The potential of farnesyltransferase inhibitors as cancer chemotherapeutics | Q41455731 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell growth | Q189159 |
| P304 | page(s) | 1831-1840 | |
| P577 | publication date | 1999-03-01 | |
| P1433 | published in | Molecular and Cellular Biology | Q3319478 |
| P1476 | title | Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. | |
| P478 | volume | 19 |
| Q33872756 | (--)-Xanthatin selectively induces GADD45γ and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells. |
| Q37549908 | 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. |
| Q44645852 | A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl |
| Q33376981 | A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study |
| Q34290291 | Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation |
| Q43924647 | Actin' up: RhoB in cancer and apoptosis |
| Q34346934 | Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis |
| Q40027619 | Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration |
| Q35179421 | An overview of farnesyltransferase inhibitors and their role in lung cancer therapy |
| Q43714923 | Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells |
| Q35429053 | Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy |
| Q33389328 | Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia |
| Q35788796 | Critical functions of RhoB in support of glioblastoma tumorigenesis |
| Q43832782 | Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase. |
| Q36946766 | Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies |
| Q46415451 | Development of farsenyl transferase inhibitors as anticancer agents |
| Q36429603 | Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies |
| Q41888779 | Developmental expression of three small GTPases in the mouse eye. |
| Q50713990 | Dictyostelium RacH regulates endocytic vesicular trafficking and is required for localization of vacuolin. |
| Q42829042 | Disrupting the transforming activity of shrimp ras(Q(61)K) by deleting the CAAX box at the C-terminus |
| Q40612680 | EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation |
| Q40902260 | Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo |
| Q42808715 | Effects of prenyl pyrophosphates on the binding of S-Ras proteins with KSR. |
| Q46091860 | Efficient prenylation by a plant geranylgeranyltransferase-I requires a functional CaaL box motif and a proximal polybasic domain. |
| Q33339999 | Enlarged meristems and delayed growth in plp mutants result from lack of CaaX prenyltransferases |
| Q57910012 | Erratum: Stress fibres take shape |
| Q33832634 | Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway |
| Q39658220 | Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype |
| Q34783592 | Farnesyl transferase inhibitors as anticancer agents |
| Q35158942 | Farnesyl transferase inhibitors in myeloid malignancies |
| Q34571777 | Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer |
| Q44615838 | Farnesyltransferase Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes |
| Q40831741 | Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli |
| Q80510506 | Farnesyltransferase inhibitors |
| Q37137960 | Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia |
| Q44588836 | Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf |
| Q35004480 | Farnesyltransferase inhibitors in breast cancer therapy |
| Q73538051 | Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects |
| Q34277794 | Farnesyltransferase inhibitors: potential role in the treatment of cancer |
| Q42822828 | GTPase stimulation in shrimp Ras(Q(61)K) with geranylgeranyl pyrophosphate but not mammalian GAP. |
| Q44970208 | Galphaq/11 signaling induces apoptosis through two pathways involving reduction of Akt phosphorylation and activation of RhoA in HeLa cells |
| Q73011261 | Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors |
| Q42817431 | Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells |
| Q55476334 | Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. |
| Q37432558 | In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells |
| Q34651534 | Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors |
| Q73898292 | Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue |
| Q78202955 | Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068 |
| Q34047193 | Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics |
| Q28205756 | Interaction of farnesylated PRL-2, a protein-tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase II |
| Q42357855 | K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells |
| Q34651253 | Lipid posttranslational modifications. Farnesyl transferase inhibitors |
| Q33669995 | Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors |
| Q42795863 | Mitogen-responsive expression of RhoB is regulated by RNA stability |
| Q39474160 | Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells |
| Q35790781 | Molecular biological design of novel antineoplastic therapies |
| Q43821528 | Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides |
| Q43869102 | Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors |
| Q74227514 | Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors |
| Q44485795 | Parallel liquid synthesis of N,N'-Disubstituted 3-amino azepin-2-ones as potent and specific farnesyl transferase inhibitors |
| Q36926772 | Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma |
| Q40596813 | Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis |
| Q36856455 | Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets |
| Q24796687 | Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity. |
| Q77434048 | Preparation and application of G protein gamma subunit-derived peptides incorporating a photoactive isoprenoid |
| Q34534438 | Prospects for anti-ras drugs |
| Q57357264 | Protein Prenylation: An (Almost) Comprehensive Overview on Discovery History, Enzymology, and Significance in Physiology and Disease |
| Q46549576 | Protein and m-RNA expression of farnesyl-transferases, RhoA and RhoB in rat liver hepatocytes: action of perillyl alcohol and vitamin A in vivo |
| Q26858942 | Protein prenylation and synaptic plasticity: implications for Alzheimer's disease |
| Q38704283 | Protein prenylation: unique fats make their mark on biology |
| Q34046314 | RAS inhibitors: potential for cancer therapeutics |
| Q36156141 | ROCK I-mediated activation of NF-kappaB by RhoB |
| Q34270496 | Ras interference as cancer therapy |
| Q36360393 | Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway |
| Q28645748 | Rho and Rac take center stage |
| Q35681634 | Rho-regulatory proteins in breast cancer cell motility and invasion |
| Q40114788 | RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. |
| Q24552386 | RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors |
| Q44119525 | RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death |
| Q53353124 | RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. |
| Q28589451 | RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells |
| Q24628907 | RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage |
| Q35331913 | RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody |
| Q49550467 | RhoB: Team Oncogene or Team Tumor Suppressor? |
| Q40667915 | Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors |
| Q35918459 | Role of farnesyltransferase inhibitors in hematologic malignancies |
| Q34348449 | Searching new targets for anticancer drug design: the families of Ras and Rho GTPases and their effectors |
| Q83324479 | Spatiotemporal organization of Ras signaling: rasosomes and the galectin switch |
| Q57369437 | Structure, biological activity and membrane partitioning of analogs of the isoprenylated a‐factor mating peptide of Saccharomyces cerevisiae |
| Q44529443 | Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors |
| Q42835076 | Synthesis and biological evaluation of 4-[(3-Methyl-3 H -imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor |
| Q42803818 | Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor |
| Q33679239 | Targeting protein prenylation for cancer therapy |
| Q35108011 | The Medical Management of Pancreatic Cancer: A Review |
| Q34241295 | The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors |
| Q24805139 | The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution |
| Q47808440 | The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest |
| Q36284222 | The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner |
| Q33961247 | The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis |
| Q35186888 | Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia |
| Q33614140 | Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. |
| Q44467311 | Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. |
| Q44619783 | Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. |
| Q40149906 | Working together: Farnesyl transferase inhibitors and statins block protein prenylation |
Search more.